| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014223358 |
| P356 | DOI | 10.1038/BJC.2013.85 |
| P932 | PMC publication ID | 3619271 |
| P698 | PubMed publication ID | 23449352 |
| P5875 | ResearchGate publication ID | 235756189 |
| P50 | author | Emmanuel Tsochatzis | Q28320718 |
| P2093 | author name string | D Hochhauser | |
| A K Burroughs | |||
| A Mayer | |||
| D Yu | |||
| E Williams | |||
| T Meyer | |||
| D Patch | |||
| N Davies | |||
| A Kirkwood | |||
| J O'Beirne | |||
| M Roughton | |||
| R Gillmore | |||
| S Beare | |||
| S P Pereira | |||
| P2860 | cites work | Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma | Q24235977 |
| CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials | Q24614759 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma | Q28247867 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Prognosis of hepatocellular carcinoma: the BCLC staging classification | Q29619984 | ||
| Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study | Q33392573 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| Chemoembolization for intermediate HCC: is there proof of survival benefit? | Q34050999 | ||
| Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma | Q34404080 | ||
| Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. | Q34581507 | ||
| Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. | Q34635723 | ||
| The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011 | Q35096101 | ||
| Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum | Q35824978 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? | Q37942465 | ||
| Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells | Q39634976 | ||
| Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma | Q39926325 | ||
| Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients | Q43850818 | ||
| Meeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomes | Q44972981 | ||
| Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). | Q46777563 | ||
| Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. | Q51082254 | ||
| A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients | Q60685449 | ||
| Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer | Q67465233 | ||
| Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodol | Q68257423 | ||
| Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study | Q72709851 | ||
| EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization | Q84441129 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase II clinical trial | Q42824440 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 1252-1259 | |
| P577 | publication date | 2013-02-28 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma | |
| P478 | volume | 108 |
| Q33621563 | A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. |
| Q43075001 | ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma |
| Q38239587 | Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review |
| Q39541816 | Clostridium perfringens infection after transarterial chemoembolization for large hepatocellular carcinoma |
| Q42362049 | Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trial |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q97520657 | Cured giant hepatocellular carcinoma after transarterial embolization complicated with liver abscess formation |
| Q92344068 | Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC) |
| Q89928773 | Downstaging for hepatocellular cancer: harm or benefit? |
| Q57756376 | Hepatocellular carcinoma |
| Q92356815 | Intermediate stage hepatocellular carcinoma: a summary review |
| Q38714207 | Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma |
| Q46800739 | Liver-directed therapy for hepatocellular carcinoma. |
| Q35951070 | Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread |
| Q28079027 | Minimally invasive image-guided therapies for hepatocellular carcinoma |
| Q38419200 | New treatment modalities for hepatocellular cancer |
| Q96134073 | Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline |
| Q37578521 | Nonsurgical treatment for localized hepatocellular carcinoma. |
| Q36278698 | Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma |
| Q92808866 | Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma |
| Q44943405 | Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors |
| Q37138263 | Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone |
| Q39261082 | Review article: delivering precision oncology in intermediate-stage liver cancer |
| Q41520341 | ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization |
| Q47788877 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. |
| Q47609170 | Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma |
| Q91713442 | Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis |
| Q92626784 | Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization |
| Q35237344 | Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
| Q35411599 | Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. |
| Q33920350 | Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. |
| Q50579308 | The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. |
| Q36043584 | Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres |
| Q37655092 | Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion |
| Q38201633 | Transarterial chemoembolization and bland embolization for hepatocellular carcinoma |
| Q38739497 | Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials |
| Q35209230 | Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review |
| Q95282127 | Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference |
| Q38626594 | Value of quality of life analysis in liver cancer: A clinician's perspective |
Search more.